Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1 Inhibitor
HIV-1 inhibitor-40 (Compound 4ab) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1 with an EC50 of 1.9 nM, demonstrating potent antiviral activity. This compound exhibits minimal interaction with cytochrome P450 enzymes, with IC50 values of 5.16 μM for CYP2C9 and 4.51 μM for CYP2C19, indicating its favorable profile for therapeutic applications. Notably, HIV-1 inhibitor-40 shows no significant acute toxicity in vivo, making it a promising candidate for further research in HIV treatment. -
HIV Inhibitor
Influenza antiviral conjugate-1 (INT-2) is an HIV inhibitor that exhibits potent cell fusion inhibition. This compound serves as a click chemistry reagent, featuring an alkyne group capable of undergoing copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its application in biological research allows for the development of innovative therapeutic strategies and the study of viral entry mechanisms. -
HIV REV/RRE Interaction Inhibitor
Niruriside is an inhibitor of the HIV REV/RRE complex, specifically targeting the interaction between the HIV REV protein and RRE RNA with an IC50 of 3.3 μM. This compound exhibits selectivity, showing no significant effects on the unrelated R17 capsid protein/operator RNA binding system. While Niruriside does not protect CEM-SS cells from acute HIV-1 infection, it serves as a valuable tool for investigating the mechanisms of HIV infection and the role of the REV/RRE interaction in viral replication and pathogenesis. -
HIV
4-Isocyanato-TEMPO is a spin labeling reagent that targets the 2'-position of RNA. This compound is instrumental in studying the dynamics of HIV-1 transactivation response RNA and hammerhead ribozyme interactions through electron paramagnetic resonance (EPR) spectroscopy. Its unique properties enable detailed investigation of RNA structures and dynamics, making it valuable in HIV research and related biochemical studies. -
HIV-1 Inhibitor
L 696229 is a selective inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), demonstrating significant antiviral activity. This compound is primarily utilized in the study of HIV replication and the development of antiretroviral therapies, offering insights into viral resistance mechanisms and potential therapeutic interventions. Its specificity for RT makes it a valuable tool in HIV research and drug discovery. -
HIV-1 Inhibitor
Fosamprenavir sodium is an orally active inhibitor targeting HIV-1 protease and functions as a prodrug for Amprenavir. Upon administration, it is hydrolyzed by cell phosphatases in the intestinal epithelium to release Amprenavir, which inhibits HIV-1 protease by binding to its active site. This binding prevents the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the maturation of infectious virus particles. Fosamprenavir sodium is valuable for research on human immunodeficiency virus (HIV-1) infection. -
Anti-HIV Activity
Interiorin is a compound derived from Kadsura heteroclita that exhibits moderate anti-HIV activity, characterized by an EC50 value of 1.6 µg/mL. This bioactive compound is of interest in antiviral research, particularly for the development of therapeutic strategies against HIV infection. Its potential to modulate viral replication makes it a valuable reagent for studies focused on HIV biology and treatment options. -
Non-Nucleoside rReverse Transcriptase Inhibitor
UC-38 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits potent anti-HIV activity. This compound disrupts the reverse transcription process essential for the viral replication cycle, making it a valuable tool for research on HIV mechanisms and potential therapeutics. Its application extends to the investigation of NNRTIs in the development of effective HIV treatment strategies. -
HIV-1 Inhibitor
HIV-1 inhibitor-35 is a potent inhibitor of HIV-1, exhibiting EC50 values of 80 nM and 70 nM against LTR and CMV in HEK293 cells, respectively. This compound also demonstrates cytotoxic activity against HepG2 liver cancer cells, with a CC50 of 40 nM. HIV-1 inhibitor-35 is suitable for research applications in HIV-1 latency reversal and antiviral therapeutic investigations. -
HIV Inhibitor
GB-1a is a biflavanone that functions as an inhibitor of HIV-1 reverse transcriptase, demonstrating an IC50 value of 236 μM and an EC50 of 38.0 μM for HIV-1 replication. This compound effectively prevents the conversion of HIV-1 genomic RNA into DNA, making it a valuable tool for research on AIDS and HIV-1 infection. Additionally, GB-1a can be naturally sourced from the heartwood of Garcinia multiflora Champ, further emphasizing its potential for biological study. -
HIV-1 Inhibitor
AIC-292 is a selective inhibitor of HIV-1 nonnucleoside reverse transcriptase, demonstrating potent antiviral activity against wild-type HIV-1 laboratory strains at low nanomolar concentrations. This compound exhibits significant in vivo efficacy in mouse xenograft models, making it a valuable tool for research into HIV-1 infection and antiretroviral therapies. AIC-292 may aid in the development of innovative therapeutic strategies targeting HIV-1. -
HIV Inhibitor
HIV-1 inhibitor-38 is a potent HIV-1 inhibitor that exhibits effective antiviral activity against the virus responsible for HIV/AIDS. Its unique mechanism of action positions it as a potential candidate for further development as a latency-reversing agent, making it a valuable tool in HIV research and therapeutic investigation. This compound is particularly relevant for studies focused on viral eradication and understanding HIV latency. -
Non-Nucleoside reverse Transcriptase Inhibitor
Bavtavirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) that targets the reverse transcriptase enzyme essential for HIV replication. It is utilized in highly active antiretroviral therapy (HAART) regimens and has significant implications in HIV disease research. Bavtavirine's mechanism of action makes it a valuable tool in studying HIV pathogenesis and developing therapeutic strategies against the virus. -
HIV-1 Inhibitor
HIV-IN-5 is a potent HIV-1 inhibitor that targets the non-nucleoside reverse transcriptase inhibitor binding pocket (NNIBP). It exhibits an IC50 value of 0.16 μM for inhibiting viral replication and demonstrates interference with HIV DNA-dependent DNA polymerization activity with an IC50 of 2.18 μM. This compound is valuable for research focused on HIV-1 antiviral mechanisms and the development of therapeutic agents targeting HIV replication. -
HIV-1 Inhibitor
HIV-1 Inhibitor-13 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. With an IC50 of 0.14 μM against HIV-1 reverse transcriptase, it demonstrates significant antiviral activity. This compound also exhibits effectiveness against various HIV-1 resistant strains, with EC50 values ranging from 2.85 to 18.0 nM, making it a valuable tool for HIV research and therapeutics development. -
HIV
4-Nitrobenzofuroxan is an antiviral compound targeting HIV-1, demonstrating significant inhibitory activity against the virus. Additionally, it shows an inhibitory effect on the enzyme IDO1. This compound is particularly relevant for research applications focused on viral infection mechanisms and potential therapeutic interventions for HIV. -
HIV-1 Inhibitor
HIV-1 Inhibitor-15 is a potent and broad-spectrum inhibitor of HIV-1, targeting various strains including HIV-1 WT, L100I, K103N, Y181C, and E138K. It demonstrates impressive inhibitory activity with EC50 values of 1.7 nM, 4 nM, 2 nM, 6 nM, and 9 nM, respectively. This compound features excellent solubility and safety profiles, along with favorable oral bioavailability, making it valuable for research applications in the study of HIV-1 treatment mechanisms and resistance. -
HIV-1 Inhibitor
U-104489 is a potent inhibitor of HIV-1, targeting the reverse transcriptase (RT) enzyme. It demonstrates Ki values of 0.13 μM against the wild-type p66/p51 variant (G190), and 0.12 μM against the G190A variant, while exhibiting significantly reduced activity (Ki > 100 μM) against the G190E variant. This compound is valuable for research applications aimed at understanding HIV-1 resistance mechanisms and developing effective antiretroviral therapies. -
Reverse Transcriptase Inhibitor
HIV-1 inhibitor-56 functions as a potent non-nucleoside reverse transcriptase inhibitor targeting the HIV-1 virus. It exhibits significant antiviral activity against wild-type HIV-1 in TZM cells, with an EC50 value of 0.24 nM, indicating strong efficacy. Additionally, HIV-1 inhibitor-56 is capable of penetrating the blood-brain barrier, making it a valuable tool for research in HIV-1-related neurological studies and therapeutic development. -
HIV-Nef Protein Inhibitor
ZINC04177596 is a potent inhibitor of the HIV-negative factor (HIV-Nef) protein. The Nef protein plays a critical role in HIV replication and contributes to the pathogenesis of AIDS. This compound is valuable for research into therapeutic strategies targeting HIV infection and understanding the molecular mechanisms underlying viral replication. -
HIV-1 Inhibitor
Patentiflorin A is a potent HIV-1 inhibitor that targets viral replication. It has demonstrated broad-spectrum activity against various strains of the virus, including those resistant to conventional treatments. This compound is valuable for research focused on understanding HIV-1 pathogenesis and developing new therapeutic strategies to combat drug-resistant strains. -
HIV-1 Inhibitor
Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl is an HIV-1 inhibitor that primarily targets the gp120 protein. By interfering with the interaction between gp120 and the CD4 receptor, this compound preserves CD4-dependent T cell function. Its inhibitory activity makes it a valuable tool for research focused on HIV-1 infection and immune response modulation. -
HIV
2′,3′-Dideoxy-5-ethyluridine (ddEtUrd) is an antiretroviral agent targeting HIV. It exhibits weak anti-HIV activity and has been evaluated for its ability to inhibit HIV replication in human MT4 lymphocytes. While its phosphorylation is crucial for its antiviral effect, the compound shows limited potency, and no strong relationship has been established between ddEtUrd’s affinity for human deoxythymidine kinase or deoxycytidine kinase and its overall efficacy. This reagent is of interest in HIV research for further exploring antiviral mechanisms. -
HIV Inhibitor
HIV-1 inhibitor-47 targets HIV-1 by inhibiting the vif-dependent degradation of human APOBEC3G, exhibiting an IC50 value of 14.33 μM. This compound is valuable in studying HIV pathogenesis and the role of host immunity involved in viral replication. Additionally, HIV-1 inhibitor-47 is implicated in the synthesis of derivatives of 1-(2-pyrimidinyl)piperazine, which may possess antianxiety, antidepressant, and antipsychotic properties, expanding its potential applications in neuropharmacology. -
HIV-1 Inhibitor
HIV-1 inhibitor-46 is a potent non-nucleoside reverse transcriptase inhibitor targeting HIV-1. With an EC50 value of 1.425 μM, it effectively hinders viral replication. This compound is valuable for research into HIV/AIDS and the development of therapeutic strategies to combat the virus. -
HIV-1 Inhibitor
HIV-1 inhibitor-39 (compound 3c) is a potent inhibitor of HIV-1 reverse transcriptase (RT), exhibiting an IC50 of 15.75 µM. This compound demonstrates significant antiviral activity against HIV-1, making it a valuable tool for research in HIV therapy. Additionally, while it shows cytotoxic effects in MT-4 cells with a CC50 of 112.9 µM, its efficacy in inhibiting viral replication positions it as a promising candidate for further investigation in HIV-related studies. -
HIV-1 Inhibitor
HIV-1 inhibitor-30 is a potent inhibitor of HIV-1 reverse transcriptase, demonstrating an EC50 of 40 nM and an IC50 of 80 nM. This compound exhibits significant antiviral activity against various non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1 strains, with IC50 values ranging from 0.04 to 1.42 μM. HIV-1 inhibitor-30 is a valuable tool for studying HIV/AIDS pathogenesis and developing therapeutic strategies against resistant viral strains. -
HIV-1 Latency-Reversing Agent
Ciapavir is an HIV-1 latency-reversing agent that targets cIAP1, facilitating the degradation of this inhibitor and subsequently activating the non-canonical NF-κB pathway. This compound effectively reverses latent HIV-1 reservoirs both in vitro and in vivo, while minimizing systemic T cell activation and broad cytokine release. Ciapavir is a valuable tool for research into HIV-1 infection and the mechanisms of latency reversal. -
HIV-1 Inhibitor
HIV-1 inhibitor-22 is a potent non-nucleoside reverse transcriptase (RT) inhibitor targeting HIV-1. It demonstrates significant antiretroviral activity, exhibiting IC50 values of 3.63 μM against HIV-1 RT and EC50 values of 0.304 μM and 0.201 μM against HIV-1 wild-type and K103N strains, respectively. Additionally, HIV-1 inhibitor-22 shows low cytotoxicity, with a CC50 greater than 227 μM, making it a valuable tool for investigating HIV-1 replication and resistance mechanisms in research applications. -
HIV-1 Entry Inhibitor
Myriceric acid B is a potent HIV-1 entry inhibitor that specifically targets the gp41 protein. This compound exhibits antiviral activity by preventing the fusion of the viral and host cell membranes, thereby inhibiting viral entry. Additionally, Myriceric acid B demonstrates antitumor properties, making it a valuable candidate for research in virology and cancer biology. -
HIV-1 RT Inhibitor
BM 21.1298 is a selective non-nucleoside inhibitor of HIV-1 reverse transcriptase (RT), targeting the viral replication process. This compound exhibits significant antiviral activity, making it a valuable tool for research in HIV pathogenesis and treatment strategies. BM 21.1298's specificity towards HIV-1 RT allows for detailed studies of enzyme function and potential therapeutic applications. -
Reverse Transcriptase Inhibitor
Dexelvucitabine is a potent nucleoside reverse transcriptase inhibitor that targets HIV-1 polymerase. This orally active compound exhibits efficacy against HIV-1 strains resistant to thymidine analogs and those harboring the M184V mutation. As a 2′-deoxycytidine analog, Dexelvucitabine serves as an important research tool for studying antiretroviral therapies and the mechanisms of drug resistance in viral infections. -
CCR5 Antagonist
CCR5 antagonist 2 is a potent inhibitor of the CCR5 receptor, exhibiting an IC50 of 8.34 nM. This compound demonstrates broad-spectrum anti-HIV-1 activity and can be utilized in research focused on HIV pathogenesis and therapy development. Its mechanism of action makes it a valuable tool for studies aimed at blocking viral entry and understanding the role of CCR5 in immune response. -
HIV-1 Reverse Transcriptase Inhibitor
Thiazolobenzimidazole is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. It effectively inhibits HIV-induced cytotoxicity and viral replication in various human cell lines, making it a valuable compound for research on HIV therapy and antiviral drug development. Its mechanism of action offers insights into potential therapeutic strategies against HIV-1 infection. -
HIV Fusion Inhibitor
Sifuvirtide is a potent HIV fusion inhibitor that targets the HIV-1 envelope glycoprotein, blocking the process of viral entry into host cells. This compound exhibits robust dose-dependent inhibition of HIV-1 mediated cell fusion and demonstrates high efficacy against various primary and laboratory-adapted HIV-1 isolates. Sifuvirtide is valuable for research applications focused on the development of anti-HIV therapeutics and studying viral entry mechanisms. -
HIV Entry Inhibitor
T-peptide is an HIV entry inhibitor that functions as a Tuftsin analog, effectively targeting HIV infection. This compound is known to mitigate cellular immunosuppression and enhance survival rates in septic mouse models. Additionally, T-peptide demonstrates the ability to inhibit the growth of residual tumor cells following surgical resection, making it a valuable tool for oncological and infectious disease research applications. -
HIV Inhibitor
HIV-IN-1 is a potent HIV inhibitor that specifically targets HIV replication mechanisms. This compound exhibits significant antiviral activity, making it suitable for research applications focused on understanding HIV infection and developing therapeutic strategies. Its efficacy in inhibiting viral replication positions HIV-IN-1 as a valuable tool in HIV-related studies. -
Anti-HIV-1 Agent
LY-73497 is a phenethylthiazolythiourea derivative that targets the HIV-1 virus. It exhibits potent anti-HIV-1 activity, making it a valuable tool in HIV research. This compound can be utilized in studies aimed at elucidating the mechanisms of viral infection and in the development of therapeutic strategies against HIV-1. -
HIV-1 Inhibitor
HIV-1 Inhibitor-28 targets the HIV-1 reverse transcriptase (RT) to effectively inhibit viral replication. This compound demonstrates high potency with an EC50 of 58 nM against wild-type HIV-1 and an IC50 of 3.37 μM for HIV-1 RT, while exhibiting low cytotoxicity in MT-4 cells (CC50 = 38.6 μM). HIV-1 Inhibitor-28 is suitable for research applications focused on AIDS and the development of antiviral therapies. -
HIV-1 Inhibitor
HIV-1 inhibitor-24 (compound S-12a) is a potent inhibitor of HIV-1 reverse transcriptase, demonstrating an IC50 value of 9.5 nM. This compound exhibits strong antiretroviral activity against wild-type HIV-1, with an EC50 of 1.6 nM, while maintaining a low cytotoxic profile (CC50 of 9.07 μM in MT-4 cells). In vivo studies indicate that HIV-1 inhibitor-24 is well tolerated at doses of 2 g/kg in mice and shows favorable cardiovascular safety, making it a valuable tool for HIV-1 research and potential therapeutic development. -
HIV Inhibitor
Globotriaosylceramide (porcine RBC) is a trihexosylceramide (Gb3) that serves as a natural resistance factor against HIV-1 infection. It is produced by the action of the synthesizing enzyme α-galactosyltransferase (A4GALT), which plays a critical role in conferring resistance to HIV-1. This compound is useful in research applications focused on understanding HIV-1 pathogenesis and exploring potential therapeutic strategies for HIV-1 infection. -
HIV-1 gp120 Peptide
Peptide T TFA is an octapeptide derived from the V2 region of the HIV-1 gp120 protein. It functions as a ligand for the CD4 receptor, effectively inhibiting the binding of HIV to this receptor. This compound is valuable in research applications focused on HIV-1 infection mechanisms and the development of potential therapeutic interventions. -
HIV-1 Inhibitor
HIV-1 inhibitor-54 is a potent HIV-1 inhibitor that targets the viral replication process. It exhibits significant anti-HIV activity in MT-4 cells, with an EC50 value of 0.032 μM against the wild-type HIV-1 strain IIIB. This compound is suitable for research applications aimed at understanding virus infection and developing antiviral strategies. -
HIV-1 Inhibitor
CNI-H0294 hydrochloride is a selective inhibitor of HIV-1 integrase, playing a crucial role in the viral life cycle by blocking the integration of viral DNA into the host genome. This compound demonstrates potential in the study of HIV-associated central nervous system diseases and can be employed in research to explore therapeutic strategies aimed at HIV infections. Its specificity for the integrase enzyme makes it an essential tool for investigating antiviral mechanisms and developing novel HIV treatments. -
HIV-1 Inhibitor
HIV-1 inhibitor-21 is a potent non-nucleoside reverse transcriptase inhibitor targeting the HIV-1 reverse transcriptase enzyme, achieving an IC50 of 0.55 μM. This compound exhibits significant antiretroviral activity against both HIV-1 wild-type and K103N strains, with EC50 values of 12.7 nM and 10.4 nM, respectively. Notably, HIV-1 inhibitor-21 demonstrates low cytotoxicity, with a CC50 of 10.2 μM in MT-4 cells, making it a valuable candidate for HIV research and therapeutic exploration. -
HIV Inhibitor
HIV-IN-3 is a potent inhibitor of HIV, exhibiting an IC50 of 1.5 μM. This compound effectively disrupts HIV replication, making it a valuable tool for studies related to HIV infections and HIV-related disease mechanisms. Its potent activity supports various research applications aimed at developing therapeutic strategies against HIV. -
HIV-1 Inhibitor
A3N19 is a potent non-nucleoside reverse transcriptase inhibitor targeting HIV-1, demonstrating an EC50 of 3.28 nM against the HIV-1 IIIB strain. This compound effectively inhibits viral replication, making it a valuable tool for research focused on HIV-1 pathogenesis and therapeutic development. Its high potency makes A3N19 suitable for detailed studies in antiviral drug efficacy and resistance mechanisms. -
HIV Inhibitor
Antiviral agent 55 is a potent inhibitor of human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2), demonstrating significant antiviral activity. It is particularly useful in research applications focused on HIV replication and pathogenesis, offering insights into potential therapeutic interventions against these viral infections. This compound allows for the exploration of antiviral mechanisms and supports the development of effective treatments for HIV. -
HIV Peptide Epitope
HIV gp120 (318-327) is a peptide epitope derived from the C-terminal region of the HIV-1 strain IIIB envelope glycoprotein. This sequence, known as the I10 peptide, is involved in the immune response and is part of the V3 peptide epitope relevant for HIV vaccine research. Although HIV gp120 (318-327) does not contain the A2 anchor residues recognized by cytotoxic T lymphocytes, it possesses structural characteristics that facilitate promiscuous binding to A2, making it valuable for studying HIV immunogenicity and vaccine development. -
HIV RT Inhibitor
(+)-Carbovir triphosphate is a potent inhibitor and substrate for HIV reverse transcriptase. This nucleotide analogue effectively impedes viral replication by interfering with the reverse transcription process. It is utilized in research applications focused on HIV drug development and the mechanistic study of reverse transcriptase inhibition.
